CRISPR Therapeutics
FDA to Review Vertex Pharmaceuticals, CRISPR Therapeutics' SCD, Beta-Thalassemia Gene-Editing Drug
The agency is expected to decide on exa-cel's sickle cell disease indication by year-end and the transfusion-dependent beta-thalassemia indication by next March.